Using apolipoprotein B to manage dyslipidemic patients: time for a change? - Wikidata - wikimedia - TriplyDB

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

http://www.wikidata.org/entity/Q33820011

about

Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008 Association of Serum Apolipoprotein B with the Increased Risk of Diabetes in Korean Men.Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.Using apolipoprotein B to manage dyslipidemia.Using Apolipoprotein B to Manage Dyslipidemia–Reply–II.Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB.Serum apolipoprotein B is inversely associated with eccentric left ventricular hypertrophy in peritoneal dialysis patients.

P2860

Q24626884-06F5A925-0D71-4F18-AEF0-4B6BFF6F9A86 Q33820018-4A7F33F8-F425-4BD0-8196-17E9FF109935 Q36621475-35E46F31-A7D1-4795-90D8-580FD00D77A7 Q37140846-5D500839-62F2-49F5-BABD-43BB719CF8A2 Q37973386-EC33E77D-1CC8-4B1F-9DB0-B51EDE70EFC8 Q42638981-46650956-C283-4F51-A569-6766E3BA78BE Q46637640-F07E53C0-9D92-4B6A-BF4B-F45527458AD6 Q47109213-45AC18F8-8B34-4CA9-9249-49D8A1868A27 Q50061267-0350DAA1-9DDA-4A64-B7E3-78D89333E9B0

P2860

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

http://www.wikidata.org/entity/Q33820011

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

@ast

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

@en

type

label

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

@ast

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

@en

prefLabel

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

@ast

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

@en

P1433

Q33820011-A764E162-7494-409C-8023-8AF6C9632855

P1476

Q33820011-DA3BD1B6-8C33-4DB4-BB47-608133876BC4

P2093

Q33820011-47E6DE96-9EDE-4636-AFEC-C7EC7D5C2386

P2860

Q33820011-0DD99AF9-E689-462D-8378-F40BAB9472FA

Q33820011-1B0EFF3D-4540-4798-9ED7-ECBF996CF1C6

Q33820011-1E6C23F8-3C4F-4955-B965-E1C23AA42779

Q33820011-24EDA1DE-0C54-4B26-A46E-D6770FBF8571

Q33820011-2B77BEF7-1191-4B24-9AE4-C7FF42A4A2B4

Q33820011-2D5676FC-E14B-442E-B6D0-D6100AA2DDB6

Q33820011-41161D98-321A-4351-BCEE-8A8291B0CD0C

Q33820011-43F5AB65-5A08-4BDA-A62B-439F396FC90C

Q33820011-4ED137A3-B03E-491F-B4B8-ED953E8E3FF3

Q33820011-6618EDFD-837D-4348-8945-55C647A2DFA9

P304

Q33820011-2F34EA04-8217-4A67-93CF-323594A91F45

P31

Q33820011-B03DDCAC-CF28-4BE3-912A-DA472E914F76

P356

Q33820011-1A1339DE-5160-4C04-AA9E-7D73430F338A

P407

Q33820011-67B3D2BA-3E1D-4E4A-926D-5AF8E9E9D70B

P433

Q33820011-E1566D53-B96D-4B8F-98E1-E9B3AC57F3CD

P478

Q33820011-5B8555D5-C5D1-4D57-9380-6EF1E250C6DC

P50

Q33820011-0F1500A8-CD40-41BA-9853-81104E0BE12E

P577

Q33820011-6DA00139-9324-4B83-9315-B58F707A9EAE

P5875

Q33820011-20A73247-4EBD-4576-A65A-9E95AB559827

P698

Q33820011-854C1BC9-A61C-4FB2-BD7C-11BF19E4B94A

P932

Q33820011-91E3F019-5F2B-40B9-9BCB-02FDD8E90E6C

P356

P1433

Mayo Clinic Proceedings

P1476

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

@en

P2093

Charles R Harper

http://www.w3.org/2001/XMLSchema#string

P2860

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Metabolic origins and clinical significance of LDL heterogeneity.

Measurement issues related to lipoprotein heterogeneity.

The forgotten majority: unfinished business in cardiovascular risk reduction.

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.

Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

The importance of non-HDL cholesterol reporting in lipid management.

P304

440-445

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4065/MCP.2009.0517

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Terry A. Jacobson

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43534830

http://www.w3.org/2001/XMLSchema#string

P698

20435837

http://www.w3.org/2001/XMLSchema#string

P932

2861973

http://www.w3.org/2001/XMLSchema#string